塞莱吉林
耐受性
医学
单胺氧化酶B
恶心
不利影响
痴呆
内科学
药理学
麻醉
单胺氧化酶
帕金森病
疾病
生物化学
化学
酶
作者
A Monteverde,P Gnemmi,Francesco Rossi,Finali Gc
出处
期刊:PubMed
日期:1990-07-01
卷期号:12 (4): 315-22
被引量:14
摘要
Selegiline, an inhibitor of monoamine oxidase B, was tested on patients with mild to moderate dementia of the Alzheimer type. Its efficacy and tolerability were compared with that of phosphatidylserine in a randomized, single-blind, parallel fashion. Forty patients (24 men and 16 women) entered the trial. Selegiline was administered in 10-mg tablets once daily and phosphatidylserine in 100-mg capsules twice daily, both treatments lasting three months. Drug efficacy was assessed at baseline and then each month by means of an extensive battery of neuropsychological tests. The assessment of drug safety was based on monitoring for adverse drug reactions and on routine laboratory tests performed before and after treatment. At the end of the study the selegiline group showed improvements statistically significantly superior to those obtained in the phosphatidylserine group on most of the cognitive areas examined. Furthermore, of particular interest was the discovery, found only in the selegiline group, of an increased degree of autonomy in day-to-day activities. Tolerability was good, the only side effect reported in both groups being slight or moderate nausea, which was severe enough to warrant withdrawal from treatment only in one case, a patient in the selegiline group with a history of gastroduodenitis.
科研通智能强力驱动
Strongly Powered by AbleSci AI